Product
Everolimus + Exemestane or CDK4/6 Inhibitor + Endocrine Therapy
1 clinical trial
2 indications
Indication
HR+ HER2- MenIndication
Advanced Breast CancerClinical trial
Treatment of Canadian Men and Pre/Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted TherapyStatus: Completed, Estimated PCD: 2022-12-01